Eli Lilly and Company (NYSE:LLY) Receives $532.78 Consensus Target Price from Analysts

Shares of Eli Lilly and Company (NYSE:LLY) have received an average recommendation of “Moderate Buy” from the twenty-one research firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and nineteen have issued a buy recommendation on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $532.78.

A number of analysts recently weighed in on LLY shares. The Goldman Sachs Group raised their price target on shares of Eli Lilly and Company from $385.00 to $470.00 and gave the company a “neutral” rating in a report on Wednesday, August 9th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $630.00 target price on shares of Eli Lilly and Company in a report on Tuesday, September 5th. StockNews.com began coverage on shares of Eli Lilly and Company in a report on Thursday, August 17th. They set a “buy” rating for the company. Bank of America boosted their price target on shares of Eli Lilly and Company from $500.00 to $600.00 in a report on Wednesday, August 9th. Finally, 22nd Century Group reissued a “maintains” rating on shares of Eli Lilly and Company in a report on Tuesday, June 27th.

Eli Lilly and Company Price Performance

NYSE LLY opened at $575.66 on Thursday. Eli Lilly and Company has a 12 month low of $296.32 and a 12 month high of $601.84. The company has a debt-to-equity ratio of 1.63, a current ratio of 1.13 and a quick ratio of 0.87. The firm has a market capitalization of $546.47 billion, a PE ratio of 80.06, a P/E/G ratio of 2.47 and a beta of 0.32. The company’s 50 day simple moving average is $512.56 and its 200 day simple moving average is $438.41.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Tuesday, August 8th. The company reported $2.11 earnings per share for the quarter, topping the consensus estimate of $1.98 by $0.13. Eli Lilly and Company had a net margin of 22.01% and a return on equity of 65.00%. The firm had revenue of $8.31 billion for the quarter, compared to analysts’ expectations of $7.58 billion. During the same period in the previous year, the company posted $1.25 EPS. The company’s quarterly revenue was up 28.1% compared to the same quarter last year. As a group, equities research analysts forecast that Eli Lilly and Company will post 9.84 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, September 8th. Investors of record on Tuesday, August 15th were given a $1.13 dividend. The ex-dividend date of this dividend was Monday, August 14th. This represents a $4.52 annualized dividend and a yield of 0.79%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 62.87%.

Insider Buying and Selling

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 34,156 shares of the business’s stock in a transaction on Tuesday, June 20th. The shares were sold at an average price of $454.08, for a total value of $15,509,556.48. Following the completion of the sale, the insider now directly owns 101,387,286 shares of the company’s stock, valued at $46,037,938,826.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, major shareholder Lilly Endowment Inc sold 34,156 shares of the company’s stock in a transaction dated Tuesday, June 20th. The shares were sold at an average price of $454.08, for a total transaction of $15,509,556.48. Following the completion of the transaction, the insider now directly owns 101,387,286 shares of the company’s stock, valued at $46,037,938,826.88. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CAO Donald A. Zakrowski sold 600 shares of the company’s stock in a transaction dated Monday, August 21st. The shares were sold at an average price of $546.51, for a total transaction of $327,906.00. Following the transaction, the chief accounting officer now directly owns 5,378 shares of the company’s stock, valued at $2,939,130.78. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,010,309 shares of company stock worth $21,095,701,670. Corporate insiders own 0.13% of the company’s stock.

Institutional Investors Weigh In On Eli Lilly and Company

Hedge funds and other institutional investors have recently bought and sold shares of the business. Retirement Group LLC raised its stake in shares of Eli Lilly and Company by 159.1% in the second quarter. Retirement Group LLC now owns 57 shares of the company’s stock worth $27,000 after buying an additional 35 shares during the period. Cornerstone Planning Group LLC bought a new stake in Eli Lilly and Company in the 2nd quarter worth approximately $33,000. Silicon Valley Capital Partners bought a new stake in Eli Lilly and Company in the 1st quarter worth approximately $25,000. Bogart Wealth LLC increased its stake in Eli Lilly and Company by 193.3% in the 1st quarter. Bogart Wealth LLC now owns 88 shares of the company’s stock worth $30,000 after acquiring an additional 58 shares during the last quarter. Finally, Activest Wealth Management bought a new stake in Eli Lilly and Company in the 2nd quarter worth approximately $40,000. Hedge funds and other institutional investors own 81.38% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.